Skip to content
10-K

Annual Report

Zevra Therapeutics, Inc. ZVRA

0001434647-26-000011

← back to feed
Filed
Mar 9, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 6, 2026 58.71M sh
Shares Diluted FY 2025 · Dec 31, 2025 57.26M sh
Shares Diluted FY 2025 · Dec 31, 2024 46.25M sh
Capex FY 2025 · Dec 31, 2025 $835K
Capex FY 2025 · Dec 31, 2024 $0
Operating Cash Flow FY 2025 · Dec 31, 2025 −$1.6M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$69.67M
Long Term Debt FY 2025 · Dec 31, 2025 $61.93M
Long Term Debt FY 2025 · Dec 31, 2024 $59.5M
Cash And Equivalents FY 2025 · Dec 31, 2025 $62.41M
Cash And Equivalents FY 2025 · Dec 31, 2024 $33.79M
Stockholders Equity FY 2025 · Dec 31, 2025 $154.66M
Stockholders Equity FY 2025 · Dec 31, 2024 $39.67M
Stockholders Equity FY 2025 · Dec 31, 2023 $61.86M
Current Liabilities FY 2025 · Dec 31, 2025 $39.28M
Current Liabilities FY 2025 · Dec 31, 2024 $34.07M
Total Liabilities FY 2025 · Dec 31, 2025 $130.07M
Total Liabilities FY 2025 · Dec 31, 2024 $138.46M
Current Assets FY 2025 · Dec 31, 2025 $223.01M
Current Assets FY 2025 · Dec 31, 2024 $86.03M
Total Assets FY 2025 · Dec 31, 2025 $284.73M
Total Assets FY 2025 · Dec 31, 2024 $178.13M
Eps Diluted FY 2025 · Dec 31, 2025 $1.35
Eps Diluted FY 2025 · Dec 31, 2024 −$2.28
Eps Basic FY 2025 · Dec 31, 2025 $1.40
Eps Basic FY 2025 · Dec 31, 2024 −$2.28
Sga Expense FY 2025 · Dec 31, 2025 $77.62M
Sga Expense FY 2025 · Dec 31, 2024 $54.87M
Net Income FY 2025 · Dec 31, 2025 $83.23M
Net Income FY 2025 · Dec 31, 2024 −$105.51M
Operating Income FY 2025 · Dec 31, 2025 −$62.94M
Operating Income FY 2025 · Dec 31, 2024 −$87M